Nanjing, China · Founded 2018 · In IPO Registration
Developer and provider of innovative antiviral and oncology therapies designed for unmet clinical needs in viral infections, cancer, and inflammatory diseases. Zenshine Pharmaceuticals (Nanjing) Group is based in Nanjing, China and was founded in 2018. Its last reported valuation was $354 million in Jan 2026. It has raised $127 million.
Last reported valuation
$354.4M
Oct 2026
Priced at
—
Total raised
$126.6M
Last round
—
Cap table — not yet on record
Zenshine Pharmaceuticals (Nanjing) Group's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Zenshine Pharmaceuticals (Nanjing) Group with a free account
·The complete investor list: 21 names
·Watch Zenshine Pharmaceuticals (Nanjing) Group: the Monday email on marks, rounds and moves
